Savara Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Savara Inc. on December 20, 2019. The filing details the entry into a Material Definitive Agreement for a private placement of equity securities and the election of a new director to the Board of Directors.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock, pre-funded warrants, and milestone warrants.
- Securities Issued: 9,569,430 shares of common stock; 5,780,537 pre-funded warrants; and milestone warrants to purchase up to 32,577,209 additional shares.
- Pricing: $1.745 per share (or $1.744 per pre-funded warrant) including accompanying milestone warrants.
- Expected Proceeds: Approximately $75,000,000 in aggregate gross proceeds if milestone warrants are exercised in full.
- Use of Proceeds: Funding a new clinical trial of Molgradex for autoimmune pulmonary alveolar proteinosis (aPAP) and general corporate purposes.
- Financial Metrics: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes and Corporate Actions
- Capital Structure: Significant dilution potential via the issuance of common stock and warrants.
- Board Composition: The Board size increased from seven to eight directors. Ricky Sun, Ph.D., was appointed to the Board effective upon the closing of the private placement.
- Investor Rights: Bain Capital Life Sciences Investors, LLC secured a right to designate a board member as long as they hold the greater of 50% of the shares purchased in this offering or 5% of outstanding shares.
- Warrant Terms: Milestone warrants are exercisable prior to the earlier of 30 days after a defined clinical milestone or two years after closing. Pre-funded warrants do not expire.
Outlook, Risks, and Contingencies
- Closing Date: Expected on or about December 24, 2019, subject to customary closing conditions.
- Beneficial Ownership Limitation: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 9.99% (or 19.99% if elected), unless the limit is waived.
- Regulatory Status: Securities were sold to accredited investors in reliance on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D; they are unregistered.
- Management Commentary: The filing does not contain specific forward-looking guidance on revenue or earnings, focusing instead on the clinical trial funding.
Key Facts for Investor Verification
- Verify the actual closing date and final gross proceeds received, as the $75 million figure is contingent on full exercise of milestone warrants.
- Confirm the specific clinical milestone definition required to trigger the exercisability of the milestone warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for additional covenants and representations.
- Monitor the impact of the new board member and Bain Capital's designation rights on future corporate governance.